Download our whitepaper,
Rare Dermatological Diseases:
Specialized Trial Approaches
What's Inside:
- Trial design strategies for ultra-rare skin conditions.
- Natural history studies and disease registries.
- Wound healing assessments in epidermolysis bullosa.
- Patient burden and trial feasibility considerations.
- Orphan drug designation for rare dermatoses.
- Gene therapy and regenerative approaches.
Access your complimentary whitepaper today:
Psoriasis
Psoriasis is a chronic and often life-altering disease characterized by the uncontrolled growth of skin cells. It is one of the most common autoimmune diseases worldwide.
In recent years, research has significantly advanced our understanding of psoriasis, uncovering its multifaceted nature involving genetic mutations, immune system dysfunction, and lifestyle and environmental factors.
This evolving knowledge has been crucial in developing current therapeutic strategies that target specific genetic mutations, utilize immune-modulating therapies, and incorporate lifestyle and environmental management.
iNGENū’s team of researchers and clinicians is dedicated to advancing psoriasis research. Through innovative trial designs and a patient-centered approach, we work to accelerate the development of new treatments that could offer improved options and outcomes for those affected by psoriasis.
50%
of patients with moderate & severe psoriasis do not achieve satisfactory results with initial treatments.
10–25%
chance of developing psoriasis if one parent has the condition.
50–70%
chance of developing psoriasis if both parents have the condition.
30%
of psoriasis patients also develop psoriatic arthritis.
Our clinical team has over
120
years of combined clinical trial experience